Summary

The global Immune Mediated Tumor Killing Assays Service market is projected to grow from US$ 264 million in 2025 to US$ 532 million by 2032, at a CAGR of 10.4% (2026-2032), driven by critical product segments and diverse end‑use applications.

Immune Mediated Tumor Killing Assays Service refers to specialized in vitro and ex vivo functional testing services used to evaluate the ability of immune effector cells to recognize, attack, and eliminate tumor target cells and to characterize how therapeutic candidates modulate this process. Assay systems typically combine tumor cells with T cells, NK cells, PBMCs, or engineered immune cells such as CAR-T, TCR-T, and CAR-NK cells in co-culture models. Depending on study objectives, testing can employ conventional two-dimensional cell systems, three-dimensional tumor spheroids, organoids, patient-derived materials, or more complex tumor microenvironment models. Tumor-cell killing is generally assessed using live-cell imaging, flow cytometry, impedance monitoring, viability-based detection, or release-based cytotoxicity methods, with immune-cell activation, proliferation, degranulation, exhaustion, and cytokine secretion used as complementary endpoints. Immune Mediated Tumor Killing Assays Service is mainly applied in the discovery, screening, mechanism-of-action evaluation, preclinical efficacy assessment, combination optimization, and potency-assay development of monoclonal antibodies, bispecific and multispecific immune-cell engagers, checkpoint therapies, and engineered cell therapies.

Key Findings
Immune Mediated Tumor Killing Assays Service is becoming an important functional assessment tool in immuno-oncology drug development
T cell, NK cell, PBMC, and engineered immune cell models form the core technical platforms
Two-dimensional assays remain widely used, while three-dimensional and patient-derived models are gaining importance
Bispecific engagers and engineered cell therapies are important sources of incremental service demand
Competition increasingly depends on model complexity, primary-cell expertise, reproducibility, and assay customization capability

Market Trends
Immune Mediated Tumor Killing Assays Service is evolving from relatively standardized cytotoxicity testing toward more physiologically relevant and multiparametric functional evaluation. Conventional two-dimensional co-culture systems remain important for candidate screening and rapid comparison because of their relatively high throughput and operational consistency, while three-dimensional spheroids, organoids, and patient-derived tumor models are increasingly used to improve translational relevance. Real-time live-cell imaging and multiparametric flow cytometry are also becoming more important because they enable continuous monitoring of killing kinetics and simultaneous assessment of immune-cell phenotype and function. As immuno-oncology pipelines move toward complex mechanisms such as T-cell redirection and engineered cellular therapies, customers increasingly require integrated assay packages that combine direct tumor-cell killing with immune activation, cytokine secretion, exhaustion, persistence, and safety-related endpoints.

Market Dynamics
Drivers
Growth in the market is mainly driven by continued innovation in immuno-oncology, particularly the development of bispecific and multispecific antibodies, T-cell engagers, CAR-T, TCR-T, CAR-NK, and other immune-cell-based therapies. These modalities require direct functional evidence that immune effector cells can selectively eliminate tumor targets under defined experimental conditions. Increasing use of combination therapies and more complex therapeutic mechanisms is also expanding the number and diversity of functional assays required during candidate screening and preclinical development. At the same time, pharmaceutical and biotechnology companies are increasingly outsourcing specialized cell-based studies to laboratories with established primary-cell resources, complex co-culture expertise, and validated analytical workflows.

Restraints
Market development is constrained by biological variability, relatively high experimental complexity, and limited standardization across laboratories. Primary immune cells from different donors can generate substantial differences in killing activity, while tumor-cell characteristics, effector-to-target conditions, culture duration, and assay readouts can materially influence results. Complex three-dimensional and patient-derived models further increase cost, experimental duration, and operational requirements. In addition, some pharmaceutical companies maintain internal immunology laboratories for strategically important programs, limiting the proportion of testing that is fully outsourced. These factors require service providers to balance biological relevance with assay reproducibility, scalability, and cost control.

Opportunities
Significant opportunities are emerging from the rapid expansion of T-cell and NK-cell redirecting therapeutics, engineered cell therapies, solid-tumor cell therapy programs, and increasingly complex combination-treatment strategies. As these therapeutic approaches move into more difficult tumor settings, developers require assay systems capable of evaluating immune-cell infiltration, serial killing, antigen heterogeneity, immune suppression, and resistance mechanisms. Three-dimensional tumor models, organoids, patient-derived tissues, and customized tumor microenvironment systems therefore provide opportunities for higher-value services. Further opportunities also exist in integrating tumor-killing assays with immune phenotyping, cytokine profiling, functional-safety assessment, and potency-method development to create more comprehensive development packages.

Challenges
The major challenge is achieving reproducible and decision-relevant results while retaining sufficient biological complexity. Immune-cell functionality can vary substantially across donors, manufacturing batches, activation states, and culture conditions, while tumor models may differ in antigen expression and sensitivity to immune-mediated killing. Service providers must therefore establish robust controls, standardized experimental procedures, appropriate donor strategies, and reliable analytical methods. Another challenge is keeping pace with rapidly evolving therapeutic modalities, which often require customized assay development rather than standardized testing. Providers must continuously expand technical expertise, cellular resources, model capabilities, and data-analysis methods while maintaining acceptable turnaround times and study reproducibility.

Value Chain Analysis
The value chain of Immune Mediated Tumor Killing Assays Service begins with access to qualified immune cells, tumor cell lines, engineered target cells, patient-derived materials, cell-culture reagents, antibodies, analytical reagents, and specialized detection platforms. Reliable sourcing and characterization of primary T cells, NK cells, PBMCs, and engineered immune cells are particularly important because biological variability directly affects assay performance. Tumor models must also be selected and characterized according to target-antigen expression, growth characteristics, immune sensitivity, and intended therapeutic mechanism.

Service providers create value through assay design, model development, cell preparation, co-culture optimization, experimental execution, multiparametric readout, data interpretation, and study reporting. Higher-value projects increasingly depend on the ability to combine functional killing assays with immune phenotyping, cytokine analysis, activation and exhaustion markers, and complex three-dimensional or patient-derived models. Downstream customers primarily include pharmaceutical companies, biotechnology companies, antibody developers, cell-therapy developers, and other organizations conducting immuno-oncology research. Competitive value is therefore determined less by routine laboratory capacity and more by scientific expertise, validated models, access to high-quality biological materials, customization capability, reproducibility, and the ability to support programs from discovery through later preclinical development.

Segment Insights
By effector cell type, T-cell-based and NK-cell-based assays represent the core service categories, while PBMC-based systems are important for assays requiring a broader and more physiologically diverse immune-cell environment. Engineered immune-cell assays are becoming increasingly important as CAR-T, TCR-T, CAR-NK, and other cell-therapy platforms expand. By assay model, conventional two-dimensional co-culture remains widely used for early-stage screening and comparative studies, whereas three-dimensional spheroids, organoids, and patient-derived ex vivo systems are gaining importance in mechanistic and translational research because they can better reflect spatial barriers, tumor heterogeneity, and immune-cell infiltration.

By therapeutic modality, antibody-based programs continue to generate demand for ADCC and related immune-effector assays, while bispecific and multispecific immune-cell engagers are creating growing demand for redirected tumor-killing studies. Cell therapies require more comprehensive functional characterization, including potency, specificity, persistence, repeated killing, and potential off-target activity. By study objective, discovery screening favors scalable and reproducible assay formats, while lead optimization, mechanism studies, preclinical efficacy evaluation, and potency development increasingly require customized models and multiparametric endpoints. These differences support a diversified service structure rather than a single standardized testing model.

Downstream Market Opportunities
The most attractive downstream opportunities are concentrated in immuno-oncology therapeutics that directly rely on immune-effector function. Bispecific and multispecific immune-cell engagers require direct demonstration of redirected cytotoxicity, while CAR-T, TCR-T, and CAR-NK programs require detailed evaluation of target-specific killing, persistence, serial killing capability, and potential off-target effects. Antibody development continues to support demand for ADCC-related studies, while checkpoint and immunomodulatory therapies increasingly require more complex tumor-immune co-culture models. As developers move into solid tumors and combination therapies, demand is shifting toward models that better reproduce tumor microenvironment constraints and provide integrated functional and mechanistic information.

Regional Insights
North America and Europe have well-established ecosystems for immuno-oncology drug discovery and outsourced preclinical research, supported by a large concentration of innovative pharmaceutical companies, biotechnology companies, specialist CROs, and cell-therapy developers. These regions remain important markets for advanced primary-cell assays, complex three-dimensional models, and customized functional studies. China is becoming an increasingly important service region as local antibody, bispecific, and cell-therapy pipelines expand and domestic CROs strengthen their capabilities in immune-cell functional assays, tumor models, and integrated preclinical services. Japan and South Korea also maintain specialized capabilities, particularly in immune-cell biology and translational testing, although the number of dedicated commercial providers is comparatively smaller.

Regional competition is increasingly influenced by access to biological materials, technical specialization, customer proximity, regulatory familiarity, and the ability to support multinational development programs. Global service providers generally compete through integrated discovery and preclinical capabilities, while regional specialists can differentiate through rapid customization, specialized models, local cell resources, and close collaboration with emerging biotechnology companies. As immuno-oncology research becomes increasingly global, cross-regional consistency in assay design and data quality is becoming more important for service providers seeking to support international drug-development programs.

Competitive Landscape Analysis
The Immune Mediated Tumor Killing Assays Service market is characterized by the coexistence of large integrated CROs and specialized immuno-oncology laboratories. Charles River Laboratories, WuXi Biologics, Labcorp, Crown Bioscience, IQVIA, Pharmaron, Reaction Biology, Oncodesign Services, Champions Oncology, Nuvisan, Concept Life Sciences, Precision for Medicine, Biocytogen, Aragen Life Sciences, Selvita, and Explicyte represent established participants with different combinations of global coverage, tumor-model expertise, immune-cell capabilities, and integrated discovery services. Specialized providers such as Cellomatics Biosciences, iQ Biosciences, PharmaLegacy, Cyagen, JOINN Laboratories, FUJIFILM Wako Bio Solutions, CellPurics, and other regional laboratories compete through focused technical capabilities, flexible assay development, or specialized cellular and tumor models. Competitive differentiation is increasingly shifting from the ability to perform basic cytotoxicity assays toward access to high-quality primary immune cells, advanced co-culture systems, three-dimensional and patient-derived models, real-time killing analysis, multiparametric immune profiling, and customized assay development. Because therapeutic mechanisms are becoming increasingly diverse, the market is expected to retain a relatively fragmented structure in which integrated global CROs and technically specialized laboratories continue to serve different customer requirements.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Immune Mediated Tumor Killing Assays Service market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
Charles River Laboratories
WuXi Biologics
Labcorp
Crown Bioscience
IQVIA
Pharmaron
Reaction Biology
Oncodesign Services
Champions Oncology
Nuvisan
Concept Life Sciences
Precision for Medicine
Biocytogen
Aragen Life Sciences
Selvita
Explicyte
Cellomatics Biosciences
Creative Bioarray
Creative Biolabs
Cyagen
GenScript Biotech
PharmaLegacy
JOINN Laboratories
iQ Biosciences
FUJIFILM Wako Bio Solutions
CellPurics
Fukushima Cell Factory
Presci

Segment by Type
T Cell-Based
NK Cell-Based
PBMC-Based
Engineered Immune Cell-Based
Other

Segment by Assay Model
2D Co-culture
3D Spheroid / Organoid
Patient-Derived Ex Vivo
Other

Segment by Therapeutic Modality
Monoclonal & Fc-Engineered Antibodies
Bispecific & Multispecific Engagers
Cell Therapies
Checkpoint & Immunomodulatory Therapies
Other

Segment by Application
Discovery Screening
Lead Optimization & Mechanism Studies
Preclinical Efficacy Evaluation
Potency Assay Development
Others

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Immune Mediated Tumor Killing Assays Service study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Immune Mediated Tumor Killing Assays Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Immune Mediated Tumor Killing Assays Service Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 T Cell-Based
1.2.3 NK Cell-Based
1.2.4 PBMC-Based
1.2.5 Engineered Immune Cell-Based
1.2.6 Other
1.3 Market Segmentation by Assay Model
1.3.1 Global Immune Mediated Tumor Killing Assays Service Market Size by Assay Model, 2021 vs 2025 vs 2032
1.3.2 2D Co-culture
1.3.3 3D Spheroid / Organoid
1.3.4 Patient-Derived Ex Vivo
1.3.5 Other
1.4 Market Segmentation by Therapeutic Modality
1.4.1 Global Immune Mediated Tumor Killing Assays Service Market Size by Therapeutic Modality, 2021 vs 2025 vs 2032
1.4.2 Monoclonal & Fc-Engineered Antibodies
1.4.3 Bispecific & Multispecific Engagers
1.4.4 Cell Therapies
1.4.5 Checkpoint & Immunomodulatory Therapies
1.4.6 Other
1.5 Market Segmentation by Application
1.5.1 Global Immune Mediated Tumor Killing Assays Service Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Discovery Screening
1.5.3 Lead Optimization & Mechanism Studies
1.5.4 Preclinical Efficacy Evaluation
1.5.5 Potency Assay Development
1.5.6 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Immune Mediated Tumor Killing Assays Service Revenue Estimates and Forecasts (2021-2032)
2.2 Global Immune Mediated Tumor Killing Assays Service Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Immune Mediated Tumor Killing Assays Service Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Immune Mediated Tumor Killing Assays Service Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 T Cell-Based: Market Share by Key Players
3.3.2 NK Cell-Based: Market Share by Key Players
3.3.3 PBMC-Based: Market Share by Key Players
3.3.4 Engineered Immune Cell-Based: Market Share by Key Players
3.3.5 Other: Market Share by Key Players
3.4 Global Immune Mediated Tumor Killing Assays Service Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Immune Mediated Tumor Killing Assays Service Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Immune Mediated Tumor Killing Assays Service Market by Assay Model
4.2.1 Global Revenue by Assay Model (2021-2032)
4.2.2 Global Revenue-Based Market Share by Assay Model (2021-2032)
4.3 Global Immune Mediated Tumor Killing Assays Service Market by Therapeutic Modality
4.3.1 Global Revenue by Therapeutic Modality (2021-2032)
4.3.2 Global Revenue-Based Market Share by Therapeutic Modality (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Immune Mediated Tumor Killing Assays Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Immune Mediated Tumor Killing Assays Service Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Immune Mediated Tumor Killing Assays Service Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Immune Mediated Tumor Killing Assays Service Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Immune Mediated Tumor Killing Assays Service Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Immune Mediated Tumor Killing Assays Service Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Immune Mediated Tumor Killing Assays Service Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Immune Mediated Tumor Killing Assays Service Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Immune Mediated Tumor Killing Assays Service Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Charles River Laboratories
11.1.1 Charles River Laboratories Corporation Information
11.1.2 Charles River Laboratories Business Overview
11.1.3 Charles River Laboratories Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.1.4 Charles River Laboratories Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.1.5 Charles River Laboratories Immune Mediated Tumor Killing Assays Service Revenue by Product in 2025
11.1.6 Charles River Laboratories Immune Mediated Tumor Killing Assays Service Revenue by Application in 2025
11.1.7 Charles River Laboratories Immune Mediated Tumor Killing Assays Service Revenue by Geographic Area in 2025
11.1.8 Charles River Laboratories Immune Mediated Tumor Killing Assays Service SWOT Analysis
11.1.9 Charles River Laboratories Recent Developments
11.2 WuXi Biologics
11.2.1 WuXi Biologics Corporation Information
11.2.2 WuXi Biologics Business Overview
11.2.3 WuXi Biologics Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.2.4 WuXi Biologics Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.2.5 WuXi Biologics Immune Mediated Tumor Killing Assays Service Revenue by Product in 2025
11.2.6 WuXi Biologics Immune Mediated Tumor Killing Assays Service Revenue by Application in 2025
11.2.7 WuXi Biologics Immune Mediated Tumor Killing Assays Service Revenue by Geographic Area in 2025
11.2.8 WuXi Biologics Immune Mediated Tumor Killing Assays Service SWOT Analysis
11.2.9 WuXi Biologics Recent Developments
11.3 Labcorp
11.3.1 Labcorp Corporation Information
11.3.2 Labcorp Business Overview
11.3.3 Labcorp Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.3.4 Labcorp Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.3.5 Labcorp Immune Mediated Tumor Killing Assays Service Revenue by Product in 2025
11.3.6 Labcorp Immune Mediated Tumor Killing Assays Service Revenue by Application in 2025
11.3.7 Labcorp Immune Mediated Tumor Killing Assays Service Revenue by Geographic Area in 2025
11.3.8 Labcorp Immune Mediated Tumor Killing Assays Service SWOT Analysis
11.3.9 Labcorp Recent Developments
11.4 Crown Bioscience
11.4.1 Crown Bioscience Corporation Information
11.4.2 Crown Bioscience Business Overview
11.4.3 Crown Bioscience Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.4.4 Crown Bioscience Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.4.5 Crown Bioscience Immune Mediated Tumor Killing Assays Service Revenue by Product in 2025
11.4.6 Crown Bioscience Immune Mediated Tumor Killing Assays Service Revenue by Application in 2025
11.4.7 Crown Bioscience Immune Mediated Tumor Killing Assays Service Revenue by Geographic Area in 2025
11.4.8 Crown Bioscience Immune Mediated Tumor Killing Assays Service SWOT Analysis
11.4.9 Crown Bioscience Recent Developments
11.5 IQVIA
11.5.1 IQVIA Corporation Information
11.5.2 IQVIA Business Overview
11.5.3 IQVIA Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.5.4 IQVIA Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.5.5 IQVIA Immune Mediated Tumor Killing Assays Service Revenue by Product in 2025
11.5.6 IQVIA Immune Mediated Tumor Killing Assays Service Revenue by Application in 2025
11.5.7 IQVIA Immune Mediated Tumor Killing Assays Service Revenue by Geographic Area in 2025
11.5.8 IQVIA Immune Mediated Tumor Killing Assays Service SWOT Analysis
11.5.9 IQVIA Recent Developments
11.6 Pharmaron
11.6.1 Pharmaron Corporation Information
11.6.2 Pharmaron Business Overview
11.6.3 Pharmaron Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.6.4 Pharmaron Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.6.5 Pharmaron Recent Developments
11.7 Reaction Biology
11.7.1 Reaction Biology Corporation Information
11.7.2 Reaction Biology Business Overview
11.7.3 Reaction Biology Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.7.4 Reaction Biology Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.7.5 Reaction Biology Recent Developments
11.8 Oncodesign Services
11.8.1 Oncodesign Services Corporation Information
11.8.2 Oncodesign Services Business Overview
11.8.3 Oncodesign Services Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.8.4 Oncodesign Services Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.8.5 Oncodesign Services Recent Developments
11.9 Champions Oncology
11.9.1 Champions Oncology Corporation Information
11.9.2 Champions Oncology Business Overview
11.9.3 Champions Oncology Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.9.4 Champions Oncology Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.9.5 Champions Oncology Recent Developments
11.10 Nuvisan
11.10.1 Nuvisan Corporation Information
11.10.2 Nuvisan Business Overview
11.10.3 Nuvisan Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.10.4 Nuvisan Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Concept Life Sciences
11.11.1 Concept Life Sciences Corporation Information
11.11.2 Concept Life Sciences Business Overview
11.11.3 Concept Life Sciences Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.11.4 Concept Life Sciences Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.11.5 Concept Life Sciences Recent Developments
11.12 Precision for Medicine
11.12.1 Precision for Medicine Corporation Information
11.12.2 Precision for Medicine Business Overview
11.12.3 Precision for Medicine Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.12.4 Precision for Medicine Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.12.5 Precision for Medicine Recent Developments
11.13 Biocytogen
11.13.1 Biocytogen Corporation Information
11.13.2 Biocytogen Business Overview
11.13.3 Biocytogen Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.13.4 Biocytogen Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.13.5 Biocytogen Recent Developments
11.14 Aragen Life Sciences
11.14.1 Aragen Life Sciences Corporation Information
11.14.2 Aragen Life Sciences Business Overview
11.14.3 Aragen Life Sciences Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.14.4 Aragen Life Sciences Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.14.5 Aragen Life Sciences Recent Developments
11.15 Selvita
11.15.1 Selvita Corporation Information
11.15.2 Selvita Business Overview
11.15.3 Selvita Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.15.4 Selvita Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.15.5 Selvita Recent Developments
11.16 Explicyte
11.16.1 Explicyte Corporation Information
11.16.2 Explicyte Business Overview
11.16.3 Explicyte Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.16.4 Explicyte Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.16.5 Explicyte Recent Developments
11.17 Cellomatics Biosciences
11.17.1 Cellomatics Biosciences Corporation Information
11.17.2 Cellomatics Biosciences Business Overview
11.17.3 Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.17.4 Cellomatics Biosciences Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.17.5 Cellomatics Biosciences Recent Developments
11.18 Creative Bioarray
11.18.1 Creative Bioarray Corporation Information
11.18.2 Creative Bioarray Business Overview
11.18.3 Creative Bioarray Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.18.4 Creative Bioarray Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.18.5 Creative Bioarray Recent Developments
11.19 Creative Biolabs
11.19.1 Creative Biolabs Corporation Information
11.19.2 Creative Biolabs Business Overview
11.19.3 Creative Biolabs Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.19.4 Creative Biolabs Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.19.5 Creative Biolabs Recent Developments
11.20 Cyagen
11.20.1 Cyagen Corporation Information
11.20.2 Cyagen Business Overview
11.20.3 Cyagen Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.20.4 Cyagen Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.20.5 Cyagen Recent Developments
11.21 GenScript Biotech
11.21.1 GenScript Biotech Corporation Information
11.21.2 GenScript Biotech Business Overview
11.21.3 GenScript Biotech Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.21.4 GenScript Biotech Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.21.5 GenScript Biotech Recent Developments
11.22 PharmaLegacy
11.22.1 PharmaLegacy Corporation Information
11.22.2 PharmaLegacy Business Overview
11.22.3 PharmaLegacy Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.22.4 PharmaLegacy Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.22.5 PharmaLegacy Recent Developments
11.23 JOINN Laboratories
11.23.1 JOINN Laboratories Corporation Information
11.23.2 JOINN Laboratories Business Overview
11.23.3 JOINN Laboratories Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.23.4 JOINN Laboratories Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.23.5 JOINN Laboratories Recent Developments
11.24 iQ Biosciences
11.24.1 iQ Biosciences Corporation Information
11.24.2 iQ Biosciences Business Overview
11.24.3 iQ Biosciences Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.24.4 iQ Biosciences Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.24.5 iQ Biosciences Recent Developments
11.25 FUJIFILM Wako Bio Solutions
11.25.1 FUJIFILM Wako Bio Solutions Corporation Information
11.25.2 FUJIFILM Wako Bio Solutions Business Overview
11.25.3 FUJIFILM Wako Bio Solutions Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.25.4 FUJIFILM Wako Bio Solutions Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.25.5 FUJIFILM Wako Bio Solutions Recent Developments
11.26 CellPurics
11.26.1 CellPurics Corporation Information
11.26.2 CellPurics Business Overview
11.26.3 CellPurics Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.26.4 CellPurics Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.26.5 CellPurics Recent Developments
11.27 Fukushima Cell Factory
11.27.1 Fukushima Cell Factory Corporation Information
11.27.2 Fukushima Cell Factory Business Overview
11.27.3 Fukushima Cell Factory Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.27.4 Fukushima Cell Factory Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.27.5 Fukushima Cell Factory Recent Developments
11.28 Presci
11.28.1 Presci Corporation Information
11.28.2 Presci Business Overview
11.28.3 Presci Immune Mediated Tumor Killing Assays Service Product Features and Attributes
11.28.4 Presci Immune Mediated Tumor Killing Assays Service Revenue and Gross Margin (2021-2026)
11.28.5 Presci Recent Developments

12 Immune Mediated Tumor Killing Assays Service Value Chain and Ecosystem Analysis
12.1 Immune Mediated Tumor Killing Assays Service Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Immune Mediated Tumor Killing Assays Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Immune Mediated Tumor Killing Assays Service Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Assay Model, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Therapeutic Modality, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Immune Mediated Tumor Killing Assays Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Immune Mediated Tumor Killing Assays Service Revenue by Region (US$ Million), 2021-2026
Table 7. Global Immune Mediated Tumor Killing Assays Service Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Immune Mediated Tumor Killing Assays Service Revenue by Players (US$ Million), 2021-2026
Table 10. Global Immune Mediated Tumor Killing Assays Service Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Immune Mediated Tumor Killing Assays Service Revenue, 2025
Table 13. Global Immune Mediated Tumor Killing Assays Service Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Immune Mediated Tumor Killing Assays Service Companies Headquarters
Table 15. Global Immune Mediated Tumor Killing Assays Service Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Immune Mediated Tumor Killing Assays Service Revenue by Type (US$ Million), 2021-2026
Table 19. Global Immune Mediated Tumor Killing Assays Service Revenue by Type (US$ Million), 2027-2032
Table 20. Global Immune Mediated Tumor Killing Assays Service Revenue by Assay Model (US$ Million), 2021-2026
Table 21. Global Immune Mediated Tumor Killing Assays Service Revenue by Assay Model (US$ Million), 2027-2032
Table 22. Global Immune Mediated Tumor Killing Assays Service Revenue by Therapeutic Modality (US$ Million), 2021-2026
Table 23. Global Immune Mediated Tumor Killing Assays Service Revenue by Therapeutic Modality (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Immune Mediated Tumor Killing Assays Service Revenue by Application (US$ Million), 2021-2026
Table 26. Global Immune Mediated Tumor Killing Assays Service Revenue by Application (US$ Million), 2027-2032
Table 27. Immune Mediated Tumor Killing Assays Service High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Immune Mediated Tumor Killing Assays Service Growth Accelerators and Market Barriers
Table 31. North America Immune Mediated Tumor Killing Assays Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Immune Mediated Tumor Killing Assays Service Growth Accelerators and Market Barriers
Table 33. Europe Immune Mediated Tumor Killing Assays Service Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Immune Mediated Tumor Killing Assays Service Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Immune Mediated Tumor Killing Assays Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Immune Mediated Tumor Killing Assays Service Investment Opportunities and Key Challenges
Table 37. Central and South America Immune Mediated Tumor Killing Assays Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Immune Mediated Tumor Killing Assays Service Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Immune Mediated Tumor Killing Assays Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Charles River Laboratories Corporation Information
Table 41. Charles River Laboratories Description and Major Businesses
Table 42. Charles River Laboratories Product Features and Attributes
Table 43. Charles River Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Charles River Laboratories Revenue Proportion by Product in 2025
Table 45. Charles River Laboratories Revenue Proportion by Application in 2025
Table 46. Charles River Laboratories Revenue Proportion by Geographic Area in 2025
Table 47. Charles River Laboratories Immune Mediated Tumor Killing Assays Service SWOT Analysis
Table 48. Charles River Laboratories Recent Developments
Table 49. WuXi Biologics Corporation Information
Table 50. WuXi Biologics Description and Major Businesses
Table 51. WuXi Biologics Product Features and Attributes
Table 52. WuXi Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. WuXi Biologics Revenue Proportion by Product in 2025
Table 54. WuXi Biologics Revenue Proportion by Application in 2025
Table 55. WuXi Biologics Revenue Proportion by Geographic Area in 2025
Table 56. WuXi Biologics Immune Mediated Tumor Killing Assays Service SWOT Analysis
Table 57. WuXi Biologics Recent Developments
Table 58. Labcorp Corporation Information
Table 59. Labcorp Description and Major Businesses
Table 60. Labcorp Product Features and Attributes
Table 61. Labcorp Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Labcorp Revenue Proportion by Product in 2025
Table 63. Labcorp Revenue Proportion by Application in 2025
Table 64. Labcorp Revenue Proportion by Geographic Area in 2025
Table 65. Labcorp Immune Mediated Tumor Killing Assays Service SWOT Analysis
Table 66. Labcorp Recent Developments
Table 67. Crown Bioscience Corporation Information
Table 68. Crown Bioscience Description and Major Businesses
Table 69. Crown Bioscience Product Features and Attributes
Table 70. Crown Bioscience Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Crown Bioscience Revenue Proportion by Product in 2025
Table 72. Crown Bioscience Revenue Proportion by Application in 2025
Table 73. Crown Bioscience Revenue Proportion by Geographic Area in 2025
Table 74. Crown Bioscience Immune Mediated Tumor Killing Assays Service SWOT Analysis
Table 75. Crown Bioscience Recent Developments
Table 76. IQVIA Corporation Information
Table 77. IQVIA Description and Major Businesses
Table 78. IQVIA Product Features and Attributes
Table 79. IQVIA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. IQVIA Revenue Proportion by Product in 2025
Table 81. IQVIA Revenue Proportion by Application in 2025
Table 82. IQVIA Revenue Proportion by Geographic Area in 2025
Table 83. IQVIA Immune Mediated Tumor Killing Assays Service SWOT Analysis
Table 84. IQVIA Recent Developments
Table 85. Pharmaron Corporation Information
Table 86. Pharmaron Description and Major Businesses
Table 87. Pharmaron Product Features and Attributes
Table 88. Pharmaron Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Pharmaron Recent Developments
Table 90. Reaction Biology Corporation Information
Table 91. Reaction Biology Description and Major Businesses
Table 92. Reaction Biology Product Features and Attributes
Table 93. Reaction Biology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Reaction Biology Recent Developments
Table 95. Oncodesign Services Corporation Information
Table 96. Oncodesign Services Description and Major Businesses
Table 97. Oncodesign Services Product Features and Attributes
Table 98. Oncodesign Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Oncodesign Services Recent Developments
Table 100. Champions Oncology Corporation Information
Table 101. Champions Oncology Description and Major Businesses
Table 102. Champions Oncology Product Features and Attributes
Table 103. Champions Oncology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Champions Oncology Recent Developments
Table 105. Nuvisan Corporation Information
Table 106. Nuvisan Description and Major Businesses
Table 107. Nuvisan Product Features and Attributes
Table 108. Nuvisan Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Nuvisan Recent Developments
Table 110. Concept Life Sciences Corporation Information
Table 111. Concept Life Sciences Description and Major Businesses
Table 112. Concept Life Sciences Product Features and Attributes
Table 113. Concept Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Concept Life Sciences Recent Developments
Table 115. Precision for Medicine Corporation Information
Table 116. Precision for Medicine Description and Major Businesses
Table 117. Precision for Medicine Product Features and Attributes
Table 118. Precision for Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Precision for Medicine Recent Developments
Table 120. Biocytogen Corporation Information
Table 121. Biocytogen Description and Major Businesses
Table 122. Biocytogen Product Features and Attributes
Table 123. Biocytogen Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Biocytogen Recent Developments
Table 125. Aragen Life Sciences Corporation Information
Table 126. Aragen Life Sciences Description and Major Businesses
Table 127. Aragen Life Sciences Product Features and Attributes
Table 128. Aragen Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Aragen Life Sciences Recent Developments
Table 130. Selvita Corporation Information
Table 131. Selvita Description and Major Businesses
Table 132. Selvita Product Features and Attributes
Table 133. Selvita Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Selvita Recent Developments
Table 135. Explicyte Corporation Information
Table 136. Explicyte Description and Major Businesses
Table 137. Explicyte Product Features and Attributes
Table 138. Explicyte Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Explicyte Recent Developments
Table 140. Cellomatics Biosciences Corporation Information
Table 141. Cellomatics Biosciences Description and Major Businesses
Table 142. Cellomatics Biosciences Product Features and Attributes
Table 143. Cellomatics Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Cellomatics Biosciences Recent Developments
Table 145. Creative Bioarray Corporation Information
Table 146. Creative Bioarray Description and Major Businesses
Table 147. Creative Bioarray Product Features and Attributes
Table 148. Creative Bioarray Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Creative Bioarray Recent Developments
Table 150. Creative Biolabs Corporation Information
Table 151. Creative Biolabs Description and Major Businesses
Table 152. Creative Biolabs Product Features and Attributes
Table 153. Creative Biolabs Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Creative Biolabs Recent Developments
Table 155. Cyagen Corporation Information
Table 156. Cyagen Description and Major Businesses
Table 157. Cyagen Product Features and Attributes
Table 158. Cyagen Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Cyagen Recent Developments
Table 160. GenScript Biotech Corporation Information
Table 161. GenScript Biotech Description and Major Businesses
Table 162. GenScript Biotech Product Features and Attributes
Table 163. GenScript Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. GenScript Biotech Recent Developments
Table 165. PharmaLegacy Corporation Information
Table 166. PharmaLegacy Description and Major Businesses
Table 167. PharmaLegacy Product Features and Attributes
Table 168. PharmaLegacy Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. PharmaLegacy Recent Developments
Table 170. JOINN Laboratories Corporation Information
Table 171. JOINN Laboratories Description and Major Businesses
Table 172. JOINN Laboratories Product Features and Attributes
Table 173. JOINN Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. JOINN Laboratories Recent Developments
Table 175. iQ Biosciences Corporation Information
Table 176. iQ Biosciences Description and Major Businesses
Table 177. iQ Biosciences Product Features and Attributes
Table 178. iQ Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. iQ Biosciences Recent Developments
Table 180. FUJIFILM Wako Bio Solutions Corporation Information
Table 181. FUJIFILM Wako Bio Solutions Description and Major Businesses
Table 182. FUJIFILM Wako Bio Solutions Product Features and Attributes
Table 183. FUJIFILM Wako Bio Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. FUJIFILM Wako Bio Solutions Recent Developments
Table 185. CellPurics Corporation Information
Table 186. CellPurics Description and Major Businesses
Table 187. CellPurics Product Features and Attributes
Table 188. CellPurics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. CellPurics Recent Developments
Table 190. Fukushima Cell Factory Corporation Information
Table 191. Fukushima Cell Factory Description and Major Businesses
Table 192. Fukushima Cell Factory Product Features and Attributes
Table 193. Fukushima Cell Factory Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Fukushima Cell Factory Recent Developments
Table 195. Presci Corporation Information
Table 196. Presci Description and Major Businesses
Table 197. Presci Product Features and Attributes
Table 198. Presci Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Presci Recent Developments
Table 200. Technologies, Platforms and Infrastructure
Table 201. Distributors List
Table 202. Market Trends and Market Evolution
Table 203. Market Drivers and Opportunities
Table 204. Market Challenges, Risks, and Restraints
Table 205. Research Programs/Design for This Report
Table 206. Key Data Information from Secondary Sources
Table 207. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. T Cell-Based Product Picture
Figure 3. NK Cell-Based Product Picture
Figure 4. PBMC-Based Product Picture
Figure 5. Engineered Immune Cell-Based Product Picture
Figure 6. Other Product Picture
Figure 7. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Assay Model, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. 2D Co-culture Product Picture
Figure 9. 3D Spheroid / Organoid Product Picture
Figure 10. Patient-Derived Ex Vivo Product Picture
Figure 11. Other Product Picture
Figure 12. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Therapeutic Modality, 2021 vs 2025 vs 2032 (US$ Million)
Figure 13. Monoclonal & Fc-Engineered Antibodies Product Picture
Figure 14. Bispecific & Multispecific Engagers Product Picture
Figure 15. Cell Therapies Product Picture
Figure 16. Checkpoint & Immunomodulatory Therapies Product Picture
Figure 17. Other Product Picture
Figure 18. Global Immune Mediated Tumor Killing Assays Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 19. Discovery Screening
Figure 20. Lead Optimization & Mechanism Studies
Figure 21. Preclinical Efficacy Evaluation
Figure 22. Potency Assay Development
Figure 23. Others
Figure 24. Immune Mediated Tumor Killing Assays Service Report Years Considered
Figure 25. Global Immune Mediated Tumor Killing Assays Service Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 26. Global Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 27. Global Immune Mediated Tumor Killing Assays Service Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 28. Global Immune Mediated Tumor Killing Assays Service Revenue-Based Market Share by Region (2021-2032)
Figure 29. Global Immune Mediated Tumor Killing Assays Service Revenue-Based Market Share Ranking (2025)
Figure 30. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 31. T Cell-Based Revenue-Based Market Share by Player in 2025
Figure 32. NK Cell-Based Revenue-Based Market Share by Player in 2025
Figure 33. PBMC-Based Revenue-Based Market Share by Player in 2025
Figure 34. Engineered Immune Cell-Based Revenue-Based Market Share by Player in 2025
Figure 35. Other Revenue-Based Market Share by Player in 2025
Figure 36. Global Immune Mediated Tumor Killing Assays Service Revenue-Based Market Share by Type (2021-2032)
Figure 37. Global Immune Mediated Tumor Killing Assays Service Revenue-Based Market Share by Assay Model (2021-2032)
Figure 38. Global Immune Mediated Tumor Killing Assays Service Revenue-Based Market Share by Therapeutic Modality (2021-2032)
Figure 39. Global Immune Mediated Tumor Killing Assays Service Revenue-Based Market Share by Application (2021-2032)
Figure 40. North America Immune Mediated Tumor Killing Assays Service Revenue YoY (US$ Million), 2021-2032
Figure 41. North America Top 5 Players Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) in 2025
Figure 42. North America Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) by Application (2021-2032)
Figure 43. US Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 44. Canada Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 45. Mexico Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 46. Europe Immune Mediated Tumor Killing Assays Service Revenue YoY (US$ Million), 2021-2032
Figure 47. Europe Top 5 Players Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) in 2025
Figure 48. Europe Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) by Application (2021-2032)
Figure 49. Germany Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 50. France Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 51. U.K. Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 52. Italy Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 53. Russia Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 54. Asia-Pacific Immune Mediated Tumor Killing Assays Service Revenue YoY (US$ Million), 2021-2032
Figure 55. Asia-Pacific Top 8 Players Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) in 2025
Figure 56. Asia-Pacific Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) by Application (2021-2032)
Figure 57. Indonesia Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 58. Japan Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 59. South Korea Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 60. Australia Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 61. India Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 62. Indonesia Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 63. Vietnam Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 64. Malaysia Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 65. Philippines Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 66. Singapore Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 67. Central and South America Immune Mediated Tumor Killing Assays Service Revenue YoY (US$ Million), 2021-2032
Figure 68. Central and South America Top 5 Players Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) in 2025
Figure 69. Central and South America Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) by Application (2021-2032)
Figure 70. Brazil Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 71. Argentina Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 72. Middle East and Africa Immune Mediated Tumor Killing Assays Service Revenue YoY (US$ Million), 2021-2032
Figure 73. Middle East and Africa Top 5 Players Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) in 2025
Figure 74. Middle East and Africa Immune Mediated Tumor Killing Assays Service Revenue (US$ Million) by Application (2021-2032)
Figure 75. GCC Countries Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 76. Israel Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 77. Egypt Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 78. South Africa Immune Mediated Tumor Killing Assays Service Revenue (US$ Million), 2021-2032
Figure 79. Immune Mediated Tumor Killing Assays Service Value Chain Mapping
Figure 80. Channels of Distribution (Direct Vs Distribution)
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed